Evidence map›Paper›PMID 31100966›Full record

ReviewCells2019

Molecular Mechanisms Responsible for Therapeutic Potential of Mesenchymal Stem Cell-Derived Secretome.

Carl Randall Harrell, Crissy Fellabaum, Nemanja Jovicic, Valentin Djonov, Nebojsa Arsenijevic, Vladislav Volarevic

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05413148 (The Effect of Wharton Jelly-derived Mesenchymal Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa), which is not on this map. Cited by 291 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
291citing papers in PubMed, 3 pooled it
37.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05413148 phase2 / phase3unknown statusnot on this mapstarted 2022, after this paper: background citation

The Effect of Wharton Jelly-derived Mesenchymal Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa

TypeinterventionalSponsorTC Erciyes UniversityRan2022 to 2023Enrolled135ConditionsRetinitis PigmentosaArmsSubtenon injection of Wharton jelly derived mesenchymal stem cells, Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes, Placebo
3 · Its place in the literature

Who cites it

291 citing papers in PubMed, 3 syntheses or guidelines pooled it, 491 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Special Issue "Biomedical Applications of Mesenchymal Stem Cells".International journal of molecular sciences · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

231 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Carl Randall HarrellRegenerative Processing Plant, LLC, Palm Harbor, FL 34176, USA. dr.harrell@regenerativeplant.org.
Crissy FellabaumRegenerative Processing Plant, LLC, Palm Harbor, FL 34176, USA. crissy@regenerativeplant.org.
Nemanja JovicicDepartment for Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozara Markovica Street, 34000 Kragujevac, Serbia. nemanjajovicic.kg@gmail.com.
Valentin DjonovInstitute of Anatomy, University of Bern, Baltzerstrasse 2, 3012 Bern, Switzerland. valentin.djonov@ana.unibe.ch.
Nebojsa ArsenijevicDepartment for Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozara Markovica Street, 34000 Kragujevac, Serbia. arne@medf.kg.ac.rs.
Vladislav VolarevicDepartment for Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozara Markovica Street, 34000 Kragujevac, Serbia. drvolarevic@yahoo.com.
University of Kragujevac · RSUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cell (MSC)-sourced secretome, defined as the set of MSC-derived bioactive factors (soluble proteins, nucleic acids, lipids and extracellular vesicles), showed therapeutic effects similar to those observed after transplantation of MSCs. MSC-derived secretome may bypass many side effects of MSC-based therapy, including unwanted differentiation of engrafted MSCs. In contrast to MSCs which had to be expanded in culture to reach optimal cell number for transplantation, MSC-sourced secretome is immediately available for treatment of acute conditions, including fulminant hepatitis, cerebral ischemia and myocardial infarction. Additionally, MSC-derived secretome could be massively produced from commercially available cell lines avoiding invasive cell collection procedure. In this review article we emphasized molecular and cellular mechanisms that were responsible for beneficial effects of MSC-derived secretomes in the treatment of degenerative and inflammatory diseases of hepatobiliary, respiratory, musculoskeletal, gastrointestinal, cardiovascular and nervous system. Results obtained in a large number of studies suggested that administration of MSC-derived secretomes represents a new, cell-free therapeutic approach for attenuation of inflammatory and degenerative diseases. Therapeutic effects of MSC-sourced secretomes relied on their capacity to deliver genetic material, growth and immunomodulatory factors to the target cells enabling activation of anti-apoptotic and pro-survival pathways that resulted in tissue repair and regeneration.

Indexed as

ImmunomodulationNeovascularization, PhysiologicRegenerationAnimalsDisease Models, AnimalHumansInflammationMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceRegenerative MedicineSecretory Pathwaydegenerative diseasesinflammatory diseasesmesenchymal stem cellssecretometherapy

Identifiers

PMID31100966
PMCPMC6562906
OpenAlexW2945162057

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.